EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical perspectives on dosimetry in molecular radiotherapy

LauraMay Davis, Caroline Elmaraghi, John R Buscombe, Mark N Gaze

Physica Medica · 2023-10 · 114 · 103154

DOI: 10.1016/j.ejmp.2023.103154 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Physica Medica, 2023-10. Verfasst von LauraMay Davis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University College London Hospitals NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Radiometry, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Molecular radiotherapy is the use of systemically administered unsealed radioactive sources to treat cancer. Theragnostics is the term used to describe paired radiopharmaceuticals localising to a specific target, one optimised for imaging, the other for therapy. For many decades, molecular radiotherapy has developed empirically. Standard administered activity schedules have been used without the prior estimation of the resulting tumour radiation absorbed dose by theragnostic imaging, or its subsequent measurement by serial scanning. This pragmatic approach has benefited many patients, however others who should have benefited have failed to do so as the radiation absorbed dose in the tumour was suboptimal. The accurate prediction and measurement of tumour and organ at risk radiation absorbed doses allows treatment to be personalised, and offers the prospect of improved clinical outcomes. To deliver this for all molecular radiotherapy patients would require not only a significant financial investment in equipment and skilled personnel, but also a change in attitude of those who believe that simple - or simplistic - schedules are easier to deliver, and that accurate dosimetry is too much trouble. Further clinical studies are required to demonstrate beyond doubt that the advantages of individualised treatment planning outweigh the inconvenience, and that the expense is justified by enhanced results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiometryNeoplasmsHumansRadiotherapy DosageRadiation DosageRadiotherapy Planning, Computer-AssistedRadiopharmaceuticalsRadiotherapy

Stichwörter der Autor:innen

Administered activityIndividualised treatmentMolecular radiotherapyPersonalised careRadiation absorbed doseTumour dosimetry

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University College London Hospitals NHS Foundation Trust, London, UK.
  • Department of Oncology, University College London Hospitals NHS Foundation Trust, 250 Euston Road, London NW1 2PG, UK.
  • Department of Nuclear Medicine, Barts Health NHS Trust, London, UK.
  • Department of Oncology, University College London Hospitals NHS Foundation Trust, 250 Euston Road, London NW1 2PG, UK. Electronic address: mgaze@nhs.net.

Förderung

  • Cancer Research UK

Zitieren

APA

Davis, L., Elmaraghi, C., Buscombe, J. R., & Gaze, M. N. (2023). Clinical perspectives on dosimetry in molecular radiotherapy. Physica Medica, 114, 103154. https://doi.org/10.1016/j.ejmp.2023.103154

Vancouver

Davis L, Elmaraghi C, Buscombe JR, Gaze MN. Clinical perspectives on dosimetry in molecular radiotherapy. Physica Medica. 2023;114:103154. doi:10.1016/j.ejmp.2023.103154

BibTeX
@article{Davis2023,
  author = {Davis, LauraMay and Elmaraghi, Caroline and Buscombe, John R and Gaze, Mark N},
  title = {Clinical perspectives on dosimetry in molecular radiotherapy},
  journal = {Physica Medica},
  year = {2023},
  volume = {114},
  pages = {103154},
  doi = {10.1016/j.ejmp.2023.103154}
}
Kostenlos starten →